Researchers found that diurnal gut microbe fluctuations are disrupted in individuals with type 2 diabetes, leading to a bacterial signature for risk profiling.
The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
A comparative genomics and machine-learning analysis spanning almost 1,000 viral genomes pointed to two proteins that appear to be altered in SARS-CoV-2 and MERS-CoV.
The New York-based firm will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various sold cancer types.
The firm believes the multi-part stratification project will help further commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
